Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Substance-Related Disorders: full-pipeline trial registry
19 of 64 indexed Substance-Related Disorders trials are currently recruiting.
Corpus placement: #215 of 28,707 conditions by registered trial count.
64 US clinical trials · 19 currently recruiting · #215 of 28,707 conditions by registered trial count
Substance-Related Disorders: 64 US clinical trials tracked, 19 recruiting.
Substance-Related Disorders is the subject of 64 registered US clinical trials on ClinicalTrials.gov, 19 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute on Drug Abuse (NIDA), running 10 of these trials.
Enrollment posture brief
Registry condition substance-related-disorders
OPEN 19 | RECR 30% | LATE 14 | EARLY 15 | RANK #215 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Chronic Obstructive Pulmonary Disease (COPD) (30% recruiting · 37 trials)
Substance-Related Disorders lists 19 open slots (30% of 64 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Substance-Related Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Substance-Related Disorders is recruiting below its size-band peers.
19 of 64 indexed trials (29.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Substance-Related Disorders research.
National Institute on Drug Abuse (NIDA) accounts for 10 of 64 trials (15.6%). 37 distinct sponsors appear on at least one study for this condition label.
-
Typical Substance-Related Disorders enrolment sits around 134 participants.
Median target enrolment is 134 among the 59 trials that report a genuine target (sentinel values excluded). 25 of those (42.4%) plan for fewer than 100 participants.
-
Substance-Related Disorders research is mostly interventional.
62 interventional and 2 observational studies make up this index (96.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
64 total, page 1 of 2
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
National Institute on Drug Abuse (NIDA)
NCT06676059
Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care
University of Pittsburgh
NCT06810076
First Face Training Evaluation in Tribal Communities
Cambridge Health Alliance
NCT05998005
Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years
Emory University
NCT05910580
Evaluating an Adverse Childhood Experience-Targeting Advocate Model of a Substance Use Prevention Program
RTI International
NCT06236100
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
Chestnut Health Systems
NCT06852170
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
University of Utah
NCT06387290
Disrupting SRFOH to Improve Substance Use and Mental Health Outcomes for Parents in Rural Regions
Chestnut Health Systems
NCT06560866
Testing Implementation Strategies to Scale-up a Multicomponent Continuum of Service Intervention for Families Involved in Systems With Parental Opioid and Methamphetamine Use
Chestnut Health Systems
NCT07365293
Phase II: Scalable Digital Delivery of CRAFT Training for Professionals to Maximize Treatment Rates of OUD in Families
We The Village
NCT06685003
Whole Health in VA Mental Health: Omnis Salutis
VA Office of Research and Development
NCT05400252
GLP-1R Agonist Treatment for Opioid Use Disorder
Milton S. Hershey Medical Center
NCT06548490
CRP and S&A for Inpatient Veterans
VA Office of Research and Development
NCT05054738
Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention
University of Maryland, College Park
NCT05973838
Motivational Interviewing at Intake vs Intake as Usual on Client Engagement in Addiction Treatment
University of New Mexi
NCT05489068
Understanding the Role of Doulas in Supporting People With PMADs
University of Montana
NCT05763537
Expression of Stress Markers During Meth Treatment (EXPRESS+)
University of California, Los Angeles
NCT05558345
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
Virginia Commonwealth University
NCT05886582
Feasibility of the 5-Step Method in the U.S.
Villanova University
NCT06565429
Scalable Digital Delivery of Evidence-based Training for Family to Maximize Treatment Admission Rates of Opioid Use Disorder in Loved Ones
We The Village
NCT05666856
Socializing a Science-Based Digital Therapeutic for Substance Use Disorders
Square2 Systems
NCT05648786
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
Yih-Ing Hser
NCT06023459
Impact of Work Activity on SUD Outcomes
VA Office of Research and Development
NCT04969081
Maternal Brain Imaging in Opioid Use Disorder
Indiana University
NCT06008990
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
University of Wisconsin, Madison
NCT05322954
Data-driven Identification for Substance Misuse
University of Wisconsin, Madison
NCT03833804
Integrating Clinical Practice Guidelines for Smoking Cessation Into Mental Health Care for Veterans With Posttraumatic Stress Disorder
US Department of Veterans Affairs
NCT00118534
Preventing Addiction Related Suicide (PARS)
University of Washington
NCT03166709
Job-Seekers Training for Patients With Drug Dependence - 1
Johns Hopkins University
NCT00102362
Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14
National Institute on Drug Abuse (NIDA)
NCT00015340
Protect and Connect: Couple HIV Prevention for Drug Involved Male Offenders
Columbia University
NCT01690494
Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment
Dartmouth-Hitchcock Medical Center
NCT01457391
Women's Treatment for Trauma and Substance Use Disorders - 1
New York State Psychiatric Institute
NCT00078156
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
National Institute on Drug Abuse (NIDA)
NCT00000318
Motivational Enhancement Therapy to Improve Treatment Utilization in Pregnant Substance Users - 1
University of Cincinnati
NCT00078143
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
National Institute on Drug Abuse (NIDA)
NCT00158288
Screening, Brief Intervention, and Referral to Treatment in Primary Care
Duke University
NCT01966432
Helping College Students With ADHD Lead Healthier Lifestyles
University of Maryland, College Park
NCT02829970
Family Intervention for Mental Illness and Substance Abuse
Dartmouth-Hitchcock Medical Center
NCT00043693
Relapse Prevention With Varenicline
Johns Hopkins University
NCT00944554
Mindfulness Meditation for the Treatment of Women With Comorbid PTSD and SUD
Medical University of South Carolina
NCT02755103
Wraparound for High-risk Families with Substance Use Disorders: Examining Family, Child, and Parent Outcomes
Dartmouth-Hitchcock Medical Center
NCT04637581
Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults
Michael J. Wesley, PhD
NCT03944954
Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)
Yale University
NCT00798538
Flupenthixol Decanoate in Methamphetamine Smoking - 1
National Institute on Drug Abuse (NIDA)
NCT00000241
Integrated Cognitive Behavioral Therapy (ICBT) for Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders
Dartmouth-Hitchcock Medical Center
NCT01457404
Buprenorphine and Integrated HIV Care
Yale University
NCT00317460
Cognitive Therapy for PTSD in Addiction Treatment
Dartmouth-Hitchcock Medical Center
NCT00685451
Scalable Digital Delivery of Evidence-based Training for Professionals to Maximize Treatment Rates of OUD in Families
We The Village
NCT05875142
We The Village Family Support Study
We The Village
NCT04250077
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 8 |
| Phase 3 | 7 |
| Phase 4 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Substance-Related Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Substance-Related Disorders trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Substance-Related Disorders page
64 registered trials, 19 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 19 Substance-Related Disorders trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute on Drug Abuse (NIDA) sponsors the most Substance-Related Disorders trials on record, review their full trial history before evaluating a specific study. See National Institute on Drug Abuse (NIDA)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Substance-Related Disorders condition card totals 64 registered trials; most-linked intervention Behavior Therapy; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.